Durham University

#AI / data analytics / healthtech / informatics #Bioscience spinout #Contract Research Organisations (CROs) #Durham University #Magnitude Biosciences

Magnitude Biosciences secures £1.3m investment

Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, has secured £1.3 million ($1.7 million) in funding to accelerate the commercialisation of VivoScan, its proprietary in vivo high-throughput screening (HTS) platform.   VivoScan is unique in providing HTS for drug discovery in a… Read More

#News

Neurons
#Aberdeen University #Durham University #Neurodegenerative disorders #Neuroscience #Nevrargenics #Preclinical investigations

Novel drug reduces neuronal death in neurodegenerative disease

New research has shown that Ellorarxine, a novel drug compound developed by biotech Nevrargenics, provides a robust neuroprotective effect and reduces neuronal death in cell models of neurodegenerative disease. The peer reviewed study published in Frontiers in Neuroscience was conducted by academics at Aberdeen and… Read More

#News